Mutation of cysteine 46 in IKK-beta increases inflammatory responses.

Abstract excerpt

Activation of IκB kinase β (IKK-β) and nuclear factor (NF)-κB signaling contributes to cancer pathogenesis and inflammatory disease; therefore, the IKK-β-NF-κB signaling pathway is a potential therapeutic target. Current drug design strategies focus on blocking NF-κB signaling by binding to specific cysteine residues on IKK-β. However, mutations in IKK-β have been found in patients who may eventually develop drug...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Arthritis, Experimental
• Share to Collagen Type II